tirzepatide heart Obesity and failure: what changes with tirzepatideBlog barnaclínic+ ESC 2025: study supports use

Discard Materials Safely: Follow your healthcare professionals instructions for throwing away the needle and syringe

February 26, 2025: FDA Removes Ozempic From Drug Shortage List On February 21, 2025, the FDA removed Ozempic from its drug-shortage list

Read More After Natcos Withdrawal, Bajaj Healthcare files for Compulsory License to Manufacture Baricitinib A recent report by The Print revealed that Indian drugmaker Bajaj Healthcare (BH) has applied to the Patent Office for a compulsory license to manufacture Eli Lillys Baricitinib

For liraglutide 3 mg (Saxenda) , NICE Technology Appraisal TA664 states treatment should be discontinued if patients do not lose at least 5% of their initial body weight after 12 weeks on the full 3 mg daily dose